Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq of human midbrain organoid models of Parkinson's Disease

ABSTRACT: RNA-seq of human midbrain organoid models of Parkinson's Disease

PROVIDER: PRJEB45026 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR5934520_1.fastq.gz	Fastqsanger.gz
	ERR5934520_2.fastq.gz	Fastqsanger.gz
	ERR5934521_1.fastq.gz	Fastqsanger.gz
	ERR5934521_2.fastq.gz	Fastqsanger.gz
	ERR5934513_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 18

Similar Datasets

RNA-seq of human midbrain organoid models of Parkinson's Disease

Project description:Parkinson’s disease (PD) is a prevalent neurodegenerative disorder that is characterized by the selective loss of midbrain dopamine (DA)-producing neurons and the formation of α-synuclein (α-syn)-containing inclusions named Lewy bodies (LBs). Here, we report that the loss of glucocerebrosidase (GCase), coupled with α-syn overexpression, result in substantial accumulation of detergent-resistant α-syn aggregates and Lewy body-like inclusions (LBLIs) in human midbrain-like organoids (hMLOs). These LBLIs exhibit a highly similar structure to PD-associated LBs, by displaying a spherically symmetric morphology with an eosinophilic core, and containing α-syn and ubiquitin. Importantly, hMLOs generated from PD patient-derived inducible pluripotent stem cells (iPSCs) harboring SNCA triplication also exhibit subsequent degeneration of DA neurons and LBLI formation upon chronic GCase inhibitor treatment. Taken together, our hMLOs harbouring two major PD risk factors (GCase deficiency and overproduced α-syn) successfully recapitulate major pathophysiological signatures of the disease, and highlight the broad utility of brain organoid technology in modeling human neurodegenerative diseases.

2021-08-13 | E-MTAB-7302 | biostudies-arrayexpress

Huamn iPSC midbrain neuron Parkinson disease

Project description:Proteomic analysis of iPSC-midbrain neuron cultures from Parkinson's disease patients haboring A53T pathogenic variant

2025-08-25 | PXD051673 | Pride

Modelling G2019S-LRRK2 sporadic Parkinson’s disease in 3D midbrain organoids

Project description:Recent advances in generating 3 dimensional (3D) organoid systems from stem cells offer new possibilities for disease modeling. In this study, we generate isogenic 3D midbrain organoids with or without a Parkinson’s disease-associated LRRK2 G2019S mutation. LRRK2-G2019S midbrain organoids derived from LRRK2 targeted human iPSCs in vitro have LRRK2-associated sporadic Parkinson's disease phenotypes. Midbrain-like 3D organoids expressing LRRK2-G2019S showed dynamic changes in globle gene expression.

2019-02-02 | GSE125234 | GEO

Reproducibility of PD patient-specific midbrain organoid data for in vitro disease modelling (timepoints)

Project description:Midbrain organoids are advanced in vitro cellular models for disease modelling. They have been used successfully over the past decade for Parkinson’s disease (PD) research and drug development. The three-dimensional structure and multicellular composition allow disease research under more physiological conditions than is possible with conventional 2D cellular models. However, there are concerns in the field regarding the organoid batch-to-batch variability and thus the reproducibility of the results. In this manuscript, we generate multiple independent midbrain organoid batches derived from healthy individuals or GBA-N370S mutation-carrying PD patients to evaluate the reproducibility of the GBA-N370S mutation-associated PD transcriptomic and metabolic signature as well as selected protein abundance. Our analysis shows that GBA-PD-associated phenotypes are reproducible across organoid generation batches and time points. This proves that midbrain organoids are not only suitable for PD in vitro modelling, but also represent robust and highly reproducible cellular models.

2025-09-18 | GSE269316 | GEO

Reproducibility of PD patient-specific midbrain organoid data for in vitro disease modelling (passages)

2025-07-08 | GSE287566 | GEO

Single-cell transcriptomics revealed molecular vulnerability in a human midbrain-like organoid model of Parkinson's Disease [MERFISH]

Project description:Single-cell transcriptomics revealed molecular vulnerability in a human midbrain-like organoid model of Parkinson's Disease [MERFISH]

| PRJNA1129999 | ENA

Single-cell transcriptomics revealed molecular vulnerability in a human midbrain-like organoid model of Parkinson's Disease [RNA-Seq]

Project description:Single-cell transcriptomics revealed molecular vulnerability in a human midbrain-like organoid model of Parkinson's Disease [RNA-Seq]

| PRJNA1129997 | ENA

Single-cell transcriptomics revealed molecular vulnerability in a human midbrain-like organoid model of Parkinson's Disease [scRNA-Seq]

Project description:Single-cell transcriptomics revealed molecular vulnerability in a human midbrain-like organoid model of Parkinson's Disease [scRNA-Seq]

| PRJNA1129998 | ENA

scRNA-seq of Human midbrain organoids differentiated from WTSIi018-B-1 (healthy) and EDi001-B (Parkinson's Disease) iPSCs

Project description:Day 49 organoid differentiation of midbrain organoids

2023-01-01 | E-MTAB-12339 | biostudies-arrayexpress

Single-cell transcriptomics revealed molecular vulnerability in a human midbrain-like organoid model of Parkinson's Disease [MERFISH]

Project description:The human midbrain-like organoid (hMLO) is a key model system for investigating pathological features of Parkinson’s disease (PD), yet how its molecular landscape relates to cellular vulnerability in PD remains unclear. We performed an in-depth single-cell characterization of our previously established hMLO model up to 150 days in vitro. Our hMLOs exhibited various physiological cell types and broad topographical patterning that resemble that of human fetal midbrain. We further identified four distinct dopamine-producing neuron (DaN) subtypes whose molecular profiles span a key transcriptomic axis in the selective vulnerability of DaNs in PD. Deletion of PARK7, a highly penetrant PD-causing gene, from hMLOs induced cell type-dependent molecular perturbations in mitochondrial activity and synapse biology, and recapitulated PD pathophysiology including α-synuclein aggregation, Lewy Body-like inclusions and DaN degeneration with extended culture. This study highlights the utility of our hMLO model in manifesting pathological features and cell type-specific vulnerability, enabling mechanistic studies into PD pathophysiology.

2025-12-04 | GSE271118 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data